BioSpace News Archive

Microbix & Ulisse Biomed Collaborate on HPV Controls & AssaysOnboarding Tools and Quality Controls for Extended Genotype HPV Assays

Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces a collaboration with Ulisse Biomed S.p.A., a company developing innovative diagnostics, theranostics, and therapeutics.

November 10, 2023
·
5 min read
Bio NC

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO®

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO ® (berotralstat) leading to a reduction in monthly attack rates in patients with hereditary angioedema (HAE) who have normal C1-inhibitor (C1-INH) level and function.

November 10, 2023
·
10 min read
KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication in Molecular Cancer Therapeutics highlighting paxalisib preclinical data stemming from the research collaboration with the Huntsman Cancer Institute at the University of Utah in Salt Lake City, UT.

November 10, 2023
·
6 min read
Business

2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023

2seventy bio, Inc . (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its third quarter 2023 financial results on Tuesday, November 14, 2023.

November 10, 2023
·
2 min read
Pharm Country

Imvax to Present New Data on Lead Program, IGV-001, at 2023 SNO Annual Meeting

Imvax, Inc. today announced two poster presentations at the 2023 Society for NeuroOncology (SNO) 28th Annual Meeting in Vancouver, British Columbia, Canada, from November 15-19, 2023.

November 10, 2023
·
2 min read
FDA

Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

Pacira BioSciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) to expand the EXPAREL® (bupivacaine liposome injectable suspension) label to include administration in adults as an adductor canal block and a sciatic nerve block in the popliteal fossa.

November 10, 2023
·
8 min read
Business

Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the quarter ended September 30, 2023 and provided a corporate update.

November 10, 2023
·
15 min read
Drug Development

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease

Ocugen, Inc. today announced that the first patient has been dosed in its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5- hRORA ).

November 10, 2023
·
4 min read
Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany

Sandoz, the global leader in generic and biosimilar medicines, has opened two new European facilities, in line with its ongoing plans to strengthen sustainable development and supply of critical medicines in Europe and beyond.

November 10, 2023
·
3 min read
Biotech Bay

Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®

Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced new data from its virology portfolio featured in two presentations at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 10-14, 2023, in Boston.

November 10, 2023
·
5 min read